The NATO Paradox: Autonomy Off the Shelf
With the old black box monopolies breaking apart, private capital has emerged to underwrite the next era of European warfare.
Manasvi Kommuri8 min read
Read ArticleArchive
All Articles
Browse market commentary, macro analysis, and student-led reporting.
MarketsGlobal Healthcare16 July 2026
AstraZeneca's Bet on the Future of COPD Treatment
A $200 million upfront payment, with milestones potentially taking the deal's total value to $1.9 billion, gives AstraZeneca exclusive rights to develop and commercialise an experimental COPD treatment outside China. More importantly, it highlights a broader shift in how Big Pharma is sourcing innovation.
AstraZenecaPharmaceuticalsBiotechChinaCOPD
Abdul Wasey Bhatti4 min read
Read ArticleThe Concentration Trap: Why Private Equity's Revival Is Leaving Most of the Industry Behind
Global PE fundraising is rising but the number of funds closing is collapsing. The industry is not recovering. It is concentrating, and the zombie firm data suggests the structural shift is already irreversible for much of the market.
Private EquityFundraisingZombie FirmsIPOPublic Markets
Alexander Eklund7 min read
Read ArticleMarkets15 July 2026
The Shipping Cartel That Ran for 15 Years
South Korea's shipping cartel ran for 15 years across three major trade routes. The case is a textbook study in how cartels form, how they enforce discipline, and why concentrated industries make collusion so hard to prevent.
ShippingCartelsSouth KoreaAntitrustOligopoly
Jay Patel9 min read
Read ArticleMarketsGlobal Healthcare10 July 2026
Inside Vertex's $10 Billion Bet on Crinetics
Vertex's $10 billion acquisition of Crinetics is about far more than adding another drug to its portfolio. It is a strategic bet on an endocrinology platform that could fuel the company's next phase of growth.
Vertex PharmaceuticalsCrinetics PharmaceuticalsBiotechnologyMergers & Acquisitions
Abdul Wasey Bhatti6 min read
Read ArticleMarketsPrivate Equity6 July 2026
From Conglomerate to Energy: KKR's £5.7bn Bet on DCC's Transformation
A £5.7bn approach for DCC is as much a bet on the Irish conglomerate's years-long transformation into an energy distributor as it is a straightforward take-private deal, and it says as much about KKR's ambitions as it does about DCC itself.
KKRDCCEnergyMergers and Acquisitions
Sonal Weerasekera7 min read
Read ArticleMarketsPrivate Equity3 July 2026
Borrowing Against Tomorrow: How Private Equity Is Living With Its Liquidity Problem
From preferred equity deals for LP stakes to carried interest loans for executives, private equity is manufacturing liquidity at every level of the food chain. The exit market remains blocked. The workarounds are getting bigger.
Private EquitySecondariesCarried InterestLiquidityMergers and Acquisitions
Alexander Eklund7 min read
Read ArticleMarketsGlobal Healthcare3 July 2026
Who Should Profit from Britain's Autism Crisis?
As NHS waiting lists for autism assessments pass 200,000, private capital is flowing into neurodiversity services – forcing the question of whether profit and patient care can ever be aligned.
Private EquityHealthcareAutismNeurodiversityNHS
Abdul Wasey Bhatti8 min read
Read ArticleAI Boom vs. Dot-Com Bubble: History doesn't repeat, it rhymes
From rocketing IPOs to frothy market sentiment, at face value, today’s AI trade unmistakably mirrors the dot-com bubble – only this time the fallout could be far more destructive.
Martim Domingos7 min read
Read ArticleMarketsPrivate Credit29 June 2026
The Bond Giant Going Private: How Pimco Is Redrawing the Credit Map
Pimco, the $2.3tn bond giant built on public markets, is quietly becoming one of the most powerful actors in private credit with mega-deals for Meta and Oracle, lending to Gulf states in wartime, and exploiting the liquidity crunch hitting rival funds.
PimcoBondsSovereign DebtData Centres
Sonal Weerasekera10 min read
Read ArticleMarketsGlobal Healthcare26 June 2026
Has the FDA Just Revived Gene Therapy?
A single FDA reversal sent Regenxbio's shares soaring and reignited optimism across gene therapy - but one favourable decision cannot solve the commercial challenges that pushed the industry into crisis.
Gene TherapyBiotechnologyFDAHealthcare
Abdul Wasey Bhatti6 min read
Read ArticleSoftware Cannot Launder Collusion: The DOJ's War on Algorithmic Pricing
The DOJ says criminal charges are now on the table for firms that use algorithms to coordinate prices. The question at the heart of the case is whether software can produce cartel-like outcomes without anyone picking up a phone.
Algorithmic PricingAntitrustCollusionRealPageCompetition
Jay Patel10 min read
Read Article